test-2
Category: Customer Opportunity
Status: Qualifying
Potential (High-Moderate-Low): Low
Add to SFA (Y/N): TBD
Client Action Required (Y/N): Yes, No
Opportunity:
NantHealth is a transformational healthcare company converging biomolecular
medicine and bioinformatics with technology services to empower physicians,
patients, payers, pharma and researchers to transcend the traditional
barriers of today’s healthcare system. NantHealth is transforming clinical
and operational delivery with real time actionable clinical data. They are
building an integrated, evidence-based, omically-informed, personalized
approach to the delivery of care and the development of next generation
healthcare solutions.
Website: nanthealth.com
Summary of Activities/Tasks:
1. March 1, 2016 – Met with Vasu Rangadass, CTO NantHealth at HIMSS.
Discussion revolved around the topic of remote patient monitoring for
cancer patients. NIH currently has a particularly strong interest is the
collection of biometric and symptoms data from cancer patients. Entra and
Nant could collaborate in the pursuit of NIH funding to evaluate the use of
a RPM technology in the collection of real-time patient biometrics and
patient-reported measures. This aligns well with NantHealth, both in terms
of the cancer focus and the collection health data for purposes of
supporting personalized clinical intervention.
2. March 20, 2016 – Spoke with Michael Neuman, Sales Director, NantHealth.
He had recently forwarded NantHealth solution brochures for review (cancer
genetic sequencing, oncology evidence based care plans, Payer-Provider
portal, EMR/Device integration, Wellness solutions).
Forward Statements and Guidance:
Michael is circling back to Vasu regarding efforts to stand up a cancer
patient registry with RPM biometric longitudinal data. Looking to push
forward the collaboration discussion.
End.
Return to Listing
COMMENT FORM.